IGFBP7 downregulation is associated with tumor progression and clinical outcome in hepatocellular carcinoma
Authors:
Open Access
- 16 February 2011
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 130 (2) , 319-327
Abstract
Insulin‐like growth factor‐binding protein 7 (IGFBP7) functions in several cellular processes including proliferation, senescence and apoptosis. This study analyzed IGFBP7 function in hepatocellular carcinoma (HCC) cells by gene manipulation and investigated the prognostic significance of IGFBP7 expression in clinical HCC samples. In this study, we investigated changes in malignant potential such as cell growth and invasiveness in an HCC cell line, PLC/PRF/5, after transfection with shRNA against IGFBP7. The extent of apoptosis and cell cycle progression were examined after the transfection. The correlation between immunohistochemically determined IGFBP7 expression and long‐term postoperative prognosis after curative resection was also investigated in clinical HCC specimens obtained from 104 patients. PLC/PRF/5 cells transfected with shRNA against IGFBP7 showed significantly more rapid growth and stronger invasiveness than control cells. Annexin V assays showed that the IGFBP7‐depleted cells were significantly more resistant to apoptosis than the control cells, and showed decreased expression of cleaved caspase‐3 and PARP. Cell cycle progression was more rapid in the IGFBP7‐suppressed cells. In clinical HCC specimens, IGFBP7 expression was judged as positive in 67 patients (64.4%) and negative in the remaining 37 patients (35.6%). The IGFBP7 downregulation correlated significantly with poor postoperative prognosis, and IGFBP7 status was identified as an independent significant prognostic factor. Our results indicated that IGFBP7 expression correlated significantly with the malignant potential in HCC cells, suggesting that the expression could be a useful prognostic marker for HCC.Keywords
This publication has 35 references indexed in Scilit:
- Insulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cellsBritish Journal of Cancer, 2010
- Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell linesMolecular Cancer Therapeutics, 2009
- Insulin-like growth factor binding protein-7 (IGFBP7) blocks vascular endothelial cell growth factor (VEGF)-induced angiogenesis in human vascular endothelial cellsEuropean Journal of Pharmacology, 2009
- Molecular prediction of early recurrence after resection of hepatocellular carcinomaEuropean Journal of Cancer, 2009
- Molecular mapping of human hepatocellular carcinoma provides deeper biological insight from genomic dataEuropean Journal of Cancer, 2008
- Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Mediated by the Secreted Protein IGFBP7Cell, 2008
- Strong suppression of tumor growth by insulin‐like growth factor‐binding protein‐related protein 1/tumor‐derived cell adhesion factor/mac25Cancer Science, 2007
- Methylation patterns of IGFBP7 in colon cancer cell lines are associated with levels of gene expressionThe Journal of Pathology, 2007
- IGFBP7 plays a potential tumor suppressor role against colorectal carcinogenesis with its expression associated with DNA hypomethylation of exon 1Journal of Zhejiang University-SCIENCE B, 2006
- Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?The Oncologist, 2006